Diagnostic and prognostic tumor markers in the gastrointestinal tract

Seminars in Surgical Oncology

Volumn 20, Issue 2, 2001, Pages 147-166

  Seregni, Ettore ^a   Ferrari, Leonardo ^a   Martinetti, Antonia ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carcinoembryonic antigen; Gastrointestinal neoplasms; Genes, APC; Genes, bcl 2; Genes, c erB2; Genes, DCC; Genes, p53; Genes, ras; Matrix metalloproteinases; Thymidine phosphorylase; Thymidylate synthase; Tumor markers,biological

Indexed keywords

ALPHA FETOPROTEIN; ANDROGEN RECEPTOR; BETA CATENIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAGENASE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; CYTOKERATIN; ESTROGEN RECEPTOR; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; SQUAMOUS CELL CARCINOMA ANTIGEN; STEROID RECEPTOR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; CANCER DIAGNOSIS; CELL CYCLE; COLORECTAL CANCER; CYTOGENETICS; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; LIVER CANCER; ONCOGENE K RAS; ONCOGENE NEU; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; ONCOGENES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034993510     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.1028     Document Type: Review

References (282)

1. Genetic markers in sporadic tumors
2. Genetics of colorectal cancer
3. A genetic model for colorectal tumorigenesis
4. The DCC gene product in cellular differentiation and colorectal tumorigenesis
5. Increased fibronectin-receptor expression in colon carcinoma derived HT 29 cells decreases tumorigenicity in nude mice
6. Mutation in the p53 tumour suppressor gene: Clues to cancer aetiology and molecular pathogenesis
7. p53, guardian of the genome
8. Replication errors in benign and malignant tumours from hereditary nonpolyposis colorectal cancer patients
9. Microsatellite instability and mutations of the transforming growth factor beta type II receptor in colorectal cancer
10. Localisation of the gene for familial adenomatous polyposis on chromosome 5
11. Tyrosin kinase receptor-activated signal transduction pathways which lead to oncogenesis
12. Genetic heterogeneity of congenital hypertrophy of the retinal pigment epithelium (CHRPE) in families with familial adenomatous polyposis
13. Correlation between the location of germline mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients
14. Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus
15. Molecular diagnosis of familial adenomatous polyposis
16. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test
17. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis
18. K-ras mutation in Greek patients with poorly and moderately differentiated tumours of the lower intestinal tract
19. The type of K-ras mutations determines prognosis in colorectal cancer
20. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis
21. K-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study
22. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer
23. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study
24. Irinotecan hydrochloride (CPT- 11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU)
25. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?
26. Allelic loss of chromosome 18q and prognosis in colorectal cancer
27. The DCC protein and prognosis in colorectal cancer
28. Survival and acquired genetic alterations in colorectal cancer
29. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer
30. The p53 tumor suppressor gene
31. Database of p53 gene somatic mutations in human tumors and cell lines
32. Participation of p53 protein in the cellular response to DNA damage
33. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
34. Wild type p53 restores cell cycle control and inhibits gene amplification cells with mutant p53 alleles
35. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
36. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
37. p53 gain of function mutations
38. Clinical and pathological associations with allelic loss in colorectal carcinoma
39. Chromosome 17p allelic loss in colorectal cancer
40. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas
41. Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features
42. p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients
43. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis
44. p53 expression in colorectal tumors
45. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers
46. p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer?
47. Expression of high p53 levels in colorectal cancer: A favourable prognostic factor
48. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study
49. Antibodies against p53 are associated with poor prognosis of colorectal cancer
50. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
51. Molecular thanatopsis: A discourse on the BCL2 family and cell death
52. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas
53. Coexpression of Bcl2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma
54. Microsatellite instability in human solid tumors
55. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
56. Identification of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer patients
57. Roles of the DNA mismatch repair genes in colorectal tumorigenesis
58. Microsatellite instability in inherited and sporadic neoplasm
59. Microsatellite instability: The mutator that mutates the other mutator
60. Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer
61. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
62. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B Stage II (T3, NO, MO) colorectal cancer
63. American joint committee on cancer prognostic factors consensus conference. Colorectal working group
64. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999
65. Inhibitors of mammalian G1 cyclin dependent kinases
66. Cyclin D1 and human neoplasia
67. Cyclin E in human cancers
68. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
69. kipl in multistage colorectal carcinogenesis
70. kipl: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancer
71. Topological control of p21/WAF1|CIP 1 expression in normal and neoplastic epithelium
72. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation
73. Regulation of pl6CDKN2 expression and its implications for cell immortalization and senescence
74. Colon cancer testing and screening
75. Cellular senescence and cancer
76. The DNA methylation paradox
77. Cancer epigenetics comes of age
78. The biology of erbB2/neu/HER-2 and its role in cancer
79. Basic science of HER-2/neu: A review
80. MYC oncogenes and human neoplastic disease
81. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridylate folates in pyrimidine nucleotide biosynthesis
82. Thymidilate synthase: A target enzyme in cancer chemotherapy
83. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
84. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance
85. Prognostic role of thymidilate synthase, thymidine phosphorilase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
86. Rapid detection of thymidylate synthase gene expression levels by semi-quantitative competitive reverse transcriptase polymerase chain reaction followed by quantitative digital image analysis
87. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: Enzyme activity and inhibition by 5fluoro-2′-deoxyuridine-5′-monophosphate
88. Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: A preliminary study
89. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity
90. Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay
91. The enzymatic synthesis of nucleosides
92. 5-ethoxy-2′deoxyuridine, a novel substrate for thymidine phosphorilase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression
93. Thymidine phosphorilase, 2-deoxy-D-ribose and angiogenesis
94. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression
95. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells
96. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas
97. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
98. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metallo-proteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis
99. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers
100. Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase 7, matrilysin
101. Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas
102. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas
103. Frequent microsatellite alterations on chromosome 3p in esophageal squamous cell carcinoma
104. Genetic alterations on chromosome 3 and 9 of esophageal cancer tissues from China
105. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas
106. Amplification and expression of the human cyclin D gene in esophageal cancer
107. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer
108. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer
109. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma
110. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding new gene information
111. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
112. A cell cycle regulator potentially involved in the genesis of many tumor types
113. p16 gene in uncultured tumors
114. Mutations and altered expression of p161NK4 in human cancer
115. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas
116. The MTS1 gene is frequently mutated in primary human esophageal tumors
117. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinomas
118. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma
119. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
120. c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
121. Human gastric carcinogenesis: A multistep and multi-factorial process - First American Cancer Society award lecture on cancer epidemiology and prevention
122. Helicobacter pylori and atrophic gastritis: Importance of the CagA status
123. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa
124. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: An immunohistochemical study
125. Molecular biology of gastric cancer
126. Chronology of p53 protein accumulation in gastric carcinogenesis
127. Molecular pathology of gastric carcinoma: Progress and prospects
128. Mutation of ras oncogene in gastric adenocarcinoma: Association with histological phenotype
129. Loss of heterozygosity and K-ras gene mutations in gastric cancer
130. P21 protein expression and ras-oncogene mutations in gastric carcinoma: Correlation with clinical data
131. Immunohistochemical analysis of ras oncogene p21 product in human gastric carcinomas and their adjacent mucosas
132. Expression of ras oncogene p21 protein in early gastric carcinoma and adjacent gastric epithelia
133. An immunohistochemical study of ras oncoprotein expression in gastric carcinoma
134. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma
135. Expression of Kirsten-ras p21 in gastric cancer correlates with tumor progression and is prognostic
136. Ha-ras oncogene product in human gastric carcinoma: Correlation with invasiveness, metastasis or prognosis
137. Expression of cellular oncogenes in human gastric carcinoma: c-myc, c-erb B2, and c-Ha-ras
138. Molecular biological observations in gastric cancer
139. An immunohistochemical study of p53 protein in the different histological subtypes of gastric carcinoma
140. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis
141. Frequent loss of heterozygosity on chromosomes 1q, 5q and 17p in human gastric carcinomas
142. p53 expression and prognosis in gastric carcinoma
143. Prognostic value of p53 protein expression for patients with gastric cancer - A multivariate analysis
144. p53 evaluation in gastric mucosa of patients with chronic Helicobacter pilori infection
145. Growth factors and oncogenes in human gastrointestinal carcinomas
146. Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma
147. Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein
148. Gastric carcinomas with microsatellite instability: Clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes
149. Frequent amplification of the cyclin E gene in human gastric carcinomas
150. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance
151. Prognostic value of cyclin E and p53 expression in gastric carcinoma
152. Reduced expression of cyclin-dependent kinase inhibitor p27Kipl is associated with advanced stage and invasiveness of gastric carcinomas
153. p27 expression and gastric carcinoma
154. Amplification and expression of a cellular oncogene (c-myc) in human gastric adenocarcinoma cells
155. Is the presence of distant metastasis associated with c-myc amplification in gastric cancer?
156. 5-fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase
157. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
158. Genetic aspects of hepatocellular carcinogenesis
159. Carcinogenesis of primary liver malignancies
160. Adenomatous hyperplasia of the liver as a precancerous lesion
161. Incidence and diagnostic features of macroregenerative nodules vs. small hepatocellular carcinoma in cirrhotic livers
162. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3
163. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas
164. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis
165. Molecular epidemiology and carcinogenesis: Endogenous and exogenous carcinogens
166. Determination of the oncogene p53 and c-erb B2 in the tumour cytosol of advanced hepatocellular carcinoma (HCC) and correlation to survival time
167. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: Comparison study of childhood and adult hepatocellular carcinoma
168. Survivin promotes cell proliferation in human hepatocellular carcinoma
169. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: Identification of three independent regions
170. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan
171. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction
172. Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors
173. Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas
174. Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver
175. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver
176. An immuno-histochemical study of the blood vessels within primary hepatocellular tumours
177. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma
178. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study
179. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis
180. Roles of gastrointestinal hormones in pancreatic cancer
181. Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective
182. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours
183. Molecular pattern of ductal pancreatic cancer
184. Immunoistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis
185. K-ras gene mutations and loss of heterozygosity at the p53 gene locus relative to histological characteristics of mucin-producing tumors of the pancreas
186. Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma
187. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: A relationship with tumor phenotype and survival
188. Diagnosis of pancreatico-biliary malignancy: Detection of gene mutations in plasma and stool
189. Molecular pathology of invasive carcinoma
190. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy
191. Immunohistochemical analysis of expression of molecular biologic factors in intraductal papillary-mucinous tumors of pancreas - Diagnostic and biologic significance
192. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease
193. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer
194. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia
195. Mutations of the DPC4/Smad4 gene in biliary tract
196. Microsatellite instability and allelic losses in neuroendocrine tumors of the gastroentero-pancreatic system
197. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours
198. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis
199. Biology of neoplasia - Role of the p16 tumor suppressor gene in cancer
200. INK4a mutations
201. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers
202. Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states
203. Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines
204. Identification of three commonly deleted regions on chromosome arm 6q in human pancreatic cancer
205. Role of turnout markers, cytogenetics
206. Growth factors and cytokines in pancreatic carcinogenesis
207. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor
208. Tumor markers
209. Immunodiagnosis of tumor
210. Clinical protocols for the application of tests for circulating tumor markers
211. Cancer markers of the 1990s
212. Demonstration of tumor specific-antigens in human colonic carcinoma by immunological tolerance and absorption techniques
213. Molecular cloning of a carcinoembyonic antigen (CEA)-gene family member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow
214. Carcinoembryonic antigen, a human tumor marker, functions as a intercellular adhesion molecule
215. The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma. The experience of the Istituto Tumori of Milan
216. Normal biology of alpha-fetoprotein
217. Alpha-fetoprotein: 25 years of study
218. Homology between the primary structure of AFP, deduced from complete DNA sequence and serum albumin
219. Primary structure of AFP and its mRNA
220. Biochemical characteristics and clinical application of alpha-fetoprotein isoforms
221. Cell-type specific receptors for alpha fetoprotein in mouse lymphoma cell line
222. Alpha-fetoprotein mediated transfer of arachidonic acid into cultured clones derived from a rat rhabdomyosarcoma
223. Activation of an alpha-fetoprotein (AFP) receptor autocrine loop in HT-29 human colon carcinoma cells
224. Alpha-fetoprotein-mediated uptake of fatty acids by human T-lymphocytes
225. AFP isoforms and their clinical significance
226. Cytokeratins in the histological diagnosis of malignant tumors
227. The tumor markers TPA, TPS, TPAcyk and CYFRA 21-1 react differently with the keratins 8,18 and 19
228. Cytokeratins and tissue polypeptide antigen
229. Radioimmunoassay for turnout antigen of human cervical squamous carcinoma
230. Heterogeneity of a tumour antigen TA-4 or squamous cell carcinoma in relation to its appearance in the circulation
231. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors
232. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene
233. Expression and function of squamous cell carcinoma antigen
234. Structure, function and gene expression of epithelial mucins
235. Colorectal carcinoma-specific antigen detection by means of monoclonal antibodies
236. A spectrum of monoclonal antibodies reactive with human mammary tumor cells
237. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3
238. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein-72 antigen
239. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
240. Carcinoembryonic antigen
241. The value of carcinoembryonic antigen measurement in clinical practice
242. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer
243. Carcinoembryonic antigen in an unselected elderly population: A four year follow-up
244. Carcinoembryonic antigen: Report of a screening study
245. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancer
246. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in nodepositive colon cancer patients
247. Prognostic significance of preoperative carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
248. CEA as a prognostic factor in colorectal cancer
249. Follow-up of patients with colorectal cancer
250. Five year follow-up after radical surgery for colorectal cancer: Results of a prospective randomized trial
251. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
252. CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer
253. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
254. Tumour markers in gastrointestinal cancers - EGTM recommendations
255. Follow-up of colorectal cancer, a meta-analysis
256. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
257. Colorectal cancer
258. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer
259. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer
260. Serial plasma carcinoembryonic antigen measurement in the management of colorectal carcinoma
261. Carcinoembryonic antigen screening: Pros and cons
262. CA 19.9 as a marker for gastrointestinal cancers: A review
263. The clinical utility of the CA 19.9 tumor associated antigen
264. The clinical validity of circulating tumor-associated antigens CEA and CA 19.9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies
265. Ca 19.9 and pancreatic adenocarcinoma
266. CA 19.9 and carcinoembryonic antigen in pancreatic cancer diagnosis
267. Evalution of CA 19.9 as a serum tumor marker in pancreatic cancer
268. CA 19.9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases
269. Determination of CA 19.9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatis
270. Comparison of preoperative serum CA 19.9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease
271. The prognostic value of preoperative serum levels of CA 19.9 and CEA in patients with pancreatic cancer
272. CA 72.4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma
273. CA 72.4: A new tumor marker for gastric cancer
274. Surgery of small hepatocellular carcinoma. Analysis of 144 cases
275. Workshop on screening for hepatocellular carcinoma
276. Hepatocellular carcinoma
277. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels
278. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein
279. Serial AFP heterogeneity changes in patients with hepatocellular carcinoma during chemotherapy
280. Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma
281. Tumour marker detection in oesophageal carcinoma
282. CYFRA 21.1 is a useful marker for esophageal squamous cell carcinoma